vimarsana.com

Latest Breaking News On - Taysha gene therapies inc - Page 6 : vimarsana.com

Head-To-Head Analysis: Taysha Gene Therapies (NASDAQ:TSHA) vs. Bavarian Nordic A/S (OTCMKTS:BVNRY)

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership. Profitability This table compares Taysha […]

Hong-kong
Taiwan
University-of-texas-southwestern-medical-center
Texas
United-states
Canada
France
Belgium
Sweden
Spain
Saudi-arabia
Australia

Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a report published on Thursday morning, Benzinga reports. Canaccord Genuity Group currently has a $7.00 price objective on the stock. TSHA has been the topic of a number of other research reports. Cantor Fitzgerald reissued an overweight […]

Victory-capital-management-inc
Canaccord-genuity-group
Capital-management
Taysha-gene-therapies-inc
Maven-securities
Capital-investment-advisors
Howard-capital-management-inc
Needham-company
Cantor-fitzgerald
Taysha-gene-therapies
Free-report

Taysha Gene Therapies (NASDAQ:TSHA) PT Raised to $7.00 at Chardan Capital

Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its price objective boosted by Chardan Capital from $5.00 to $7.00 in a research note published on Thursday morning, Benzinga reports. They currently have a buy rating on the stock. A number of other research firms have also weighed in on TSHA. JMP Securities reissued a market […]

Chicago
Illinois
United-states
Nasdaq
Exome-asset-management
Chicago-partners-investment-group
Vanguard-group-inc
Taysha-gene-therapies-inc
Goldman-sachs-group-inc
Virtu-financial
Cantor-fitzgerald

Taysha Gene Therapies (NASDAQ:TSHA) PT Raised to $7.00 at Needham & Company LLC

Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its price target boosted by Needham & Company LLC from $5.00 to $7.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. Separately, Cantor Fitzgerald reaffirmed an overweight rating and issued a $7.00 price target on […]

Acuta-capital-partners
Cantor-fitzgerald
Taysha-gene-therapies-inc
Needham-company
Vanguard-group-inc
Taysha-gene-therapies
Free-report
Gene-therapies
Capital-partners
Vanguard-group
Get-free-report

Cantor Fitzgerald Reiterates "Overweight" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Cantor Fitzgerald restated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a report released on Wednesday morning, Benzinga reports. Cantor Fitzgerald currently has a $7.00 target price on the stock. Separately, Needham & Company LLC lifted their target price on shares of Taysha Gene Therapies from $5.00 to $7.00 […]

Citigroup-inc
Needham-company
Taysha-gene-therapies-inc
Acuta-capital-partners
Cantor-fitzgerald
Taysha-gene-therapies
Free-report
Gene-therapies
Capital-partners
Adage-capital-partners
Get-free-report

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.